Adjuvant (cisplatin, etoposide, and 5-fluorouracil) chemotherapy after curative resection of gastric adenocarcinomas involving the esophagogastric junction

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 22, Issue 3, 1999, Pages 253-257

  Ryoo, Baek Yeol ^a   Kang, Yoon Koo ^a   Im, Young Hyuck ^a   Kim, Yong Jo ^a   Kim, Bong Seog ^a   Kim, Tae You ^a   Jung, Sook Hy ang ^a   Park, Jong Ho ^a   Baek, Hee Jong ^a   Kim, You Cheoul ^a   Shim, Young Mog ^a,b   Kim, Chang Min ^a   Zo, Jae Ill ^a  

^a Korea Cancer Center Hospital   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

5 fluorouracil; Adjuvant chemotherapy; Cisplatin; Etoposide; Gastric adenocarcinoma Esophagogastric junction; PEF

Indexed keywords

CISPLATIN; ETOPOSIDE; FLUOROURACIL;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOPENIA; LOWER ESOPHAGUS SPHINCTER; MALE; PROGNOSIS; STOMACH ADENOCARCINOMA;

EID: 19244371152     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199906000-00008     Document Type: Article

References (24)

1. Webb JN, Busuttil A. Adenocarcinoma of the oesophagus and of the oesophagogastric junction. Br J Surg 1978;65:475-9.
2. Sons HU, Borchard F. Cancer of the distal esophagus and cardia. Ann Surg 1986;203:188-95.
3. Siewert JR, Stein HJ. Carcinoma of the cardia: carcinoma of the gastroesophigeal junction-classification, pathology and extent of resection. Dis Esophagus 1996;9:173-82.
4. Kajiyama Y, Tsurumaru M, Udagawa H, et al. Prognostic factors in adenocarcinoma of the gastric cardia: pathologic stage analysis and multivariate regression analysis. J Clin Oncol 1997;15:2015-21.
5. Yeum KS, Jo HJ, Kang YK, et al. Phase II study of PEF (cisplatin (P), VP-16(E), 5-fluorouracil(F)) chemotherapy for metastatic gastric cancer [abstract], Korean J Intern Med 1990:326.
6. The SAS system for windows [computer program]. Release 6.11. Cary, NC: SAS Institute, 1995.
7. Alfonso A, Rosen P, Guerra O, Fortner J. Adenocarcinoma of the proximal third of the stomach. Pitfalls in surgical management. Am J Surg 1977;134:326-30.
8. Stone R, Rangel DM, Gordon HE, Wilson SE. Carcinoma of the gastroesophageal junction. A ten-year experience with esophagogastrectomy. Am J Surg 1977;134:70-6.
9. Ellis FH Jr, Gibb SP, Watkins E Jr. Adequacy of margins of resection in gastrectomy for cancer. Ann Surg 1983;198:531-40.
10. Paolini A, Tosato F, Cassese K, et al. Total gastrectomy in the treatment of adenocarcinoma of the cardia. Review of the results in 73 resected patients. Am J Surg 1996;151:238-43.
11. Hennessy TPJ, Keeling P. Adenocarcinoma of the esophagus and cardia, J Thorac Cardiovasc Surg 1987;94:64-8.
12. Coombes RC, Schein PS, Chilvers CED, et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. J Clin Oncol 1990;8: 1362-9.
13. Estape J, Grau JJ, Alcobendas F, et al. Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up. Ann Surg 1991;213:219-221.
14. Hermans J, Bonenkamp JJ, Boon MC. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993;11:1441-7.
15. Alexander HR, Kelsen DG, Tepper JC. Cancer of the stomach. In: Devita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. Vol 1. 5th ed. Philadelphia & New York: Lippincott-Raven, 1997:1021-54.
16. Seifert P, Baker LH, Reed ML, Vaitkevicius VK. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975;36: 123-8.
17. Aabo K, Pedersen K, Rorth M. Cisplatin in the treatment of advanced gastric carcinoma: a phase II study. Cancer Treat Rep 1985;69:449-50.
18. Lacave AJ, Wils J, Diaz-Rubio E, et al. Cis-platinum as secondline chemotherapy in advanced gastric adenocarcinoma: a phase II study of the EORTC gastrointestinal tract cancer cooperative group. Eur J Cancer Clin Oncol 1985;21:1321-4.
19. Perry MC, Green MR, Mick R, Schein P. Cisplatin in patients with gastric cancer: a cancer and leukemia group B phase II study. Cancer Treat Rep 1986;70:415-6.
20. Schabel FM Jr, Trader MW, Laster WR Jr, Corbett TH, Griswold DP Jr. Cis-dichlorodiammineplatinum (II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 1979;63:1459-73.
21. Decker DA, Drelichman A, Jacobs J, et al. Adjuvant chemotherapy with cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of the head and neck. Cancer 1983;51:1353-5.
22. Kim NK, Park YS, Heo DS, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71:3813-8.
23. Elliot TE, Moertel CG, Wieand HS, et al. A phase II study of the combination of etoposide and cisplatin in the therapy of advanced gastric cancer. Cancer 1990;65:1491-1494.
24. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-7.